0
/28
1
0
7
8
0
%
0
/28
1
0
7
8
0
%
The Insomnia Severity Index (ISI) is a validated, patient-reported outcome measure designed to quantify the subjective severity of insomnia symptoms and their impact on daily functioning. Developed by Charles Morin and colleagues in 2001 at Universite Laval in Quebec, Canada, the ISI has become the most widely used insomnia assessment instrument in both clinical practice and sleep research worldwide.
Insomnia is the most prevalent sleep disorder, affecting approximately 10-15% of adults with chronic insomnia disorder and 30-35% with occasional insomnia symptoms. The condition is associated with significant adverse health outcomes including depression, anxiety, cardiovascular disease, cognitive impairment, and reduced quality of life. The economic burden of insomnia, including healthcare costs, workplace productivity losses, and accident-related expenses, is estimated at over $100 billion annually in the United States alone.
The ISI comprises seven items assessed on a 5-point Likert scale (0-4), yielding a total score from 0 to 28. Three items evaluate the core insomnia symptoms defined by the International Classification of Sleep Disorders (ICSD-3): difficulty falling asleep (sleep onset insomnia), difficulty staying asleep (sleep maintenance insomnia), and early morning awakening. Four additional items assess sleep satisfaction, daytime functioning impairment, noticeability of sleep problems to others, and distress or worry caused by sleep difficulties.
Psychometric validation studies have consistently demonstrated the ISI's strong reliability and validity. Internal consistency is excellent (Cronbach's alpha 0.74-0.91 across studies). The ISI correlates significantly with polysomnographic measures, sleep diary parameters, and other validated sleep questionnaires. It has demonstrated sensitivity to treatment change in numerous clinical trials of cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, with a reduction of 8 or more points considered a clinically meaningful response.
The ISI is endorsed by multiple clinical guidelines and expert consensus statements for insomnia assessment. The American Academy of Sleep Medicine (AASM) recommends its use in the evaluation and management of chronic insomnia disorder. It serves as a primary or secondary outcome measure in the majority of contemporary insomnia treatment trials and is recommended for both initial assessment and treatment monitoring.
In clinical settings, the ISI offers a brief yet comprehensive assessment that can be completed in under 5 minutes. It captures the multidimensional nature of insomnia, including both the sleep disturbance itself and its perceived impact on daytime function and quality of life. Serial administration allows tracking of treatment response and guides clinical decisions regarding therapy modification.
The ISI has been translated and validated in over 20 languages, facilitating its use in international research and diverse clinical populations. Cutoff scores have been established for insomnia diagnosis (10-11 optimal cutoff for community samples, 14 for research) and for tracking treatment response (reduction of 6-8 points indicates meaningful clinical improvement).
This calculator implements the standard ISI scoring algorithm with severity classifications aligned with published validation data, providing clinicians and patients with a validated tool for insomnia assessment and monitoring.
The ISI sums seven items, each rated 0-4, producing a total score of 0-28. Items assess: difficulty falling asleep, staying asleep, and early waking (core symptoms); plus sleep satisfaction, noticeability to others, worry about sleep, and daytime interference (impact measures). Severity categories: 0-7 no clinically significant insomnia, 8-14 subthreshold insomnia, 15-21 moderate clinical insomnia, 22-28 severe clinical insomnia.
Score 0-7: No clinically significant insomnia — sleep hygiene education may suffice. Score 8-14: Subthreshold insomnia — sleep hygiene optimization and monitoring recommended; consider CBT-I if persistent. Score 15-21: Moderate clinical insomnia — CBT-I is first-line treatment; pharmacotherapy may be considered as adjunct. Score 22-28: Severe clinical insomnia — comprehensive evaluation for comorbidities; CBT-I plus pharmacotherapy often needed; sleep study may be indicated to rule out other sleep disorders.
Inputs
Results
Score of 5: no clinically significant insomnia; general sleep hygiene recommendations appropriate.
Inputs
Results
Score of 19: moderate clinical insomnia; CBT-I strongly recommended as first-line treatment.
The ISI is a 7-item self-report questionnaire that measures insomnia severity and its impact on daily life. Developed by Charles Morin in 2001, it is the most widely used insomnia assessment tool in clinical practice and research. Total scores range from 0-28, with validated cutoff points for severity classification.
Scores of 15-21 indicate moderate clinical insomnia, and 22-28 indicate severe clinical insomnia. A score of 10-11 is the optimal cutoff for identifying insomnia in community samples, while a cutoff of 14-15 is commonly used in research settings to identify cases warranting clinical intervention.
The ISI is typically administered before treatment and at regular intervals (e.g., weekly during CBT-I, monthly during pharmacotherapy). A reduction of 8 or more points is considered a clinically meaningful treatment response. Post-treatment scores below 8 indicate remission of insomnia symptoms.
Cognitive Behavioral Therapy for Insomnia (CBT-I) is a structured, evidence-based psychological treatment that addresses the thoughts and behaviors perpetuating insomnia. It includes sleep restriction, stimulus control, cognitive restructuring, and relaxation techniques. Guidelines recommend it as first-line over medications due to sustained efficacy without dependence risk.
No. The ISI measures subjective insomnia severity but cannot diagnose underlying sleep disorders such as obstructive sleep apnea, restless legs syndrome, or circadian rhythm disorders. A polysomnography (sleep study) may be indicated when clinical evaluation suggests a comorbid sleep disorder or when insomnia is refractory to standard treatment.
The ISI has been validated primarily in adult populations. Modified versions exist for adolescents and older adults. For children, the Children's Sleep Habits Questionnaire (CSHQ) is more appropriate. For elderly patients, the ISI remains valid but should be interpreted alongside consideration of age-related sleep architecture changes.
Chronic insomnia impairs concentration, memory, decision-making, and reaction time. It increases risks of workplace accidents, motor vehicle crashes, depression, anxiety, and cardiovascular disease. The ISI captures this impact through items assessing functional impairment, noticeability to others, and distress, providing a comprehensive clinical picture.
Yes. FDA-approved insomnia medications (e.g., suvorexant, lemborexant, eszopiclone, zolpidem) typically reduce ISI scores by 6-10 points in clinical trials. However, medication effects may not persist after discontinuation. CBT-I produces similar magnitude improvements with more durable benefits and is preferred as first-line treatment.
Chronic insomnia typically develops through the 3P model: Predisposing factors (genetics, temperament), Precipitating factors (stressors, illness), and Perpetuating factors (poor sleep habits, excessive time in bed, worry about sleep). While precipitating factors may resolve, perpetuating factors maintain insomnia chronically.
For initial assessment: once at baseline. During active treatment: weekly during CBT-I (typically 6-8 weeks), or monthly during pharmacotherapy. After treatment: at 1, 3, 6, and 12 months for relapse monitoring. For chronic management: every 3-6 months or when symptoms change.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
CAGE Questionnaire (Alcohol)
Psychiatric Assessment Tools
Fagerstrom Test for Nicotine Dependence
Psychiatric Assessment Tools
MDQ (Mood Disorder Questionnaire)
Psychiatric Assessment Tools
Young Mania Rating Scale (YMRS)
Psychiatric Assessment Tools
PANSS (Positive and Negative Syndrome Scale)
Psychiatric Assessment Tools
AUDIT-C (Alcohol Use Disorders)
Psychiatric Assessment Tools
